Two additional companies have recently joined the Tel Aviv Stock Exchange (TASE) High-Tech Analysis Project. They will join the 20 companies already reviewed by two international companies - Edison and Frost & Sullivan.
The additional companies are:
- Clal Biotechnology Industries - which invests in R&D companies in the field of life sciences and medical technology.
- Algomizer - which markets and develops software for automation and optimization of marketing and advertising services on the Internet, to agencies and advertisers.
Following is the list of the companies that are already participating in the project:
- Biomed companies - Intec Pharma, Allium, Aposense*, BioLight, BioLineRx*, BiondVax, Brainsway*, DNA Biomed*, Kitov* Cellect, Pluristem, Collplant and Redhill.
- Technology companies - Ellomay, Energix, Vonetize, Nano Dimension, Safe T, Pointer and Foresight.
Data from the TASE's research unit indicates that most of the companies participating in the project recorded a significant increase in trading volumes, compared to their volume in the months preceding publication of the initial analysis. Also, in dual-listed shares, trading volumes in the US also increased.
The overall trading turnover in most of the analyzed shares increased by 1.6 times and up to more than 10 times in this period (except for Foresight shares, where trading turnover increased 40 times, and Intec and Allium shares, where trading volumes declined during the period under review).
In addition, most companies recorded a significant increase in the holdings of mutual funds and Israeli institutional investors in the long term, and there was a greater interest of investors, which assisted in private placements and public offerings.
The participating companies enjoyed exposure to thousands of international investors from about 30 countries around the world, hundreds of which are institutional and sophisticated investors.
About the Analysis Project
The project was launched in 2016 in order to raise the investors' level of knowledge of about technology and biomed companies and the markets in which the companies operate, thus creating appropriate pricing and increasing the exposure of investors from Israel and abroad.
In order to maintain professional, independent and unbiased analysis, the analyzed companies signed an agreement with the TASE to receive the analysis services for an obligatory period of two years. The companies cannot withdraw from the project during this period. The analysis is funded by the companies, surveyed with funding from the TASE and the Chief Scientist.
The analyses are published in the Magna and Maya sites in English and also include an Hebrew summary for investors in the local market. The analyses will be published, at least four times a year, following the publication of the companies' financial statements. In addition, updates will be published upon the occurrence of a significant event in a company that requires updating in the latest analytical work. The English analyses are published by the research companies worldwide, through the main information distributors, and large distribution boards.
View all the analyses published in the framework of the project
* Initial analysis of these companies will be published in the upcoming weeks.